CN109769392A - 苯并咪唑衍生物的酸加成盐 - Google Patents
苯并咪唑衍生物的酸加成盐 Download PDFInfo
- Publication number
- CN109769392A CN109769392A CN201780058396.7A CN201780058396A CN109769392A CN 109769392 A CN109769392 A CN 109769392A CN 201780058396 A CN201780058396 A CN 201780058396A CN 109769392 A CN109769392 A CN 109769392A
- Authority
- CN
- China
- Prior art keywords
- formula
- salt
- acid
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
酸加成盐 | 土壤沉淀或不沉淀 |
富马酸 | 沉淀 |
草酸 | 沉淀 |
柠檬酸 | 沉淀 |
L-焦谷氨酸 | 维持均质溶液 |
L-苹果酸 | 维持均质溶液 |
L-酒石酸 | 维持均质溶液 |
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0120996 | 2016-09-21 | ||
KR1020160120996A KR101829706B1 (ko) | 2016-09-21 | 2016-09-21 | 벤즈이미다졸 유도체의 산부가염 |
PCT/KR2017/010332 WO2018056697A1 (ko) | 2016-09-21 | 2017-09-20 | 벤즈이미다졸 유도체의 산부가염 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109769392A true CN109769392A (zh) | 2019-05-17 |
CN109769392B CN109769392B (zh) | 2022-06-24 |
Family
ID=61387666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780058396.7A Active CN109769392B (zh) | 2016-09-21 | 2017-09-20 | 苯并咪唑衍生物的酸加成盐 |
Country Status (13)
Country | Link |
---|---|
US (3) | US11535610B2 (zh) |
EP (1) | EP3517528B1 (zh) |
JP (1) | JP6814891B2 (zh) |
KR (1) | KR101829706B1 (zh) |
CN (1) | CN109769392B (zh) |
AR (1) | AR109679A1 (zh) |
ES (1) | ES2896802T3 (zh) |
JO (1) | JOP20170172B1 (zh) |
MX (1) | MX2019003171A (zh) |
MY (1) | MY197242A (zh) |
PH (1) | PH12019500602A1 (zh) |
TW (1) | TWI659028B (zh) |
WO (1) | WO2018056697A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200024413A (ko) * | 2018-08-28 | 2020-03-09 | 에이치케이이노엔 주식회사 | 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물 |
JOP20190201A1 (ar) * | 2018-08-29 | 2020-02-29 | Hk Inno N Corp | تركيبة لاستئصال الملوية البوابية |
EP3927340A4 (en) * | 2019-02-18 | 2022-11-02 | HK inno.N Corporation | PHARMACEUTICAL COMPOSITION WITH BENZIMIDAZOLE DERIVATIVE COMPOUND |
CA3182245A1 (en) * | 2020-06-12 | 2021-12-16 | Jae Hee Cheon | Pharmaceutical composition comprising benzimidazole derivative compound |
WO2022086238A1 (en) * | 2020-10-23 | 2022-04-28 | Hk Inno.N Corporation | Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof |
TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Lg化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
WO2023106842A1 (ko) * | 2021-12-08 | 2023-06-15 | (주) 팜젠사이언스 | 벤즈이미다졸 유도체 화합물 및 이의 용도 |
KR20230114163A (ko) | 2022-01-24 | 2023-08-01 | 엠에프씨 주식회사 | 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006134460A1 (en) * | 2005-06-14 | 2006-12-21 | Pfizer Japan Inc. | Chromane substituted benzimidazole derivatives as acid pump antagonists |
US20070142448A1 (en) * | 2005-12-19 | 2007-06-21 | Pfizer Inc. | Chromane Substituted Benzimidazole Derivatives |
WO2010000469A2 (en) * | 2008-07-03 | 2010-01-07 | Ratiopharm Gmbh | Crystalline salts of sitagliptin |
WO2016117814A2 (ko) * | 2015-01-20 | 2016-07-28 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042485A1 (en) * | 2003-10-30 | 2005-05-12 | Sk Chemicals, Co., Ltd. | Acid added salts of amlodipine |
EP1695973A1 (en) * | 2005-02-24 | 2006-08-30 | Neuro3D | Ocaperidone salt and pharmaceutical compositions containing the same |
TW201920110A (zh) * | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
KR101605063B1 (ko) | 2009-07-09 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제 |
KR102262743B1 (ko) | 2017-07-07 | 2021-06-09 | 에이치케이이노엔 주식회사 | 주사용 조성물 |
-
2016
- 2016-09-21 KR KR1020160120996A patent/KR101829706B1/ko active IP Right Grant
-
2017
- 2017-09-20 CN CN201780058396.7A patent/CN109769392B/zh active Active
- 2017-09-20 TW TW106132329A patent/TWI659028B/zh active
- 2017-09-20 JP JP2019536803A patent/JP6814891B2/ja active Active
- 2017-09-20 MX MX2019003171A patent/MX2019003171A/es active IP Right Grant
- 2017-09-20 EP EP17853411.1A patent/EP3517528B1/en active Active
- 2017-09-20 US US16/334,427 patent/US11535610B2/en active Active
- 2017-09-20 ES ES17853411T patent/ES2896802T3/es active Active
- 2017-09-20 JO JOP/2017/0172A patent/JOP20170172B1/ar active
- 2017-09-20 WO PCT/KR2017/010332 patent/WO2018056697A1/ko unknown
- 2017-09-20 MY MYPI2019001511A patent/MY197242A/en unknown
- 2017-09-20 AR ARP170102591A patent/AR109679A1/es unknown
-
2019
- 2019-03-19 PH PH12019500602A patent/PH12019500602A1/en unknown
-
2022
- 2022-11-21 US US17/990,806 patent/US11912690B2/en active Active
-
2024
- 2024-01-16 US US18/413,666 patent/US20240150331A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006134460A1 (en) * | 2005-06-14 | 2006-12-21 | Pfizer Japan Inc. | Chromane substituted benzimidazole derivatives as acid pump antagonists |
US20070142448A1 (en) * | 2005-12-19 | 2007-06-21 | Pfizer Inc. | Chromane Substituted Benzimidazole Derivatives |
CN101341149A (zh) * | 2005-12-19 | 2009-01-07 | 辉瑞大药厂 | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 |
CN101341149B (zh) * | 2005-12-19 | 2011-06-08 | 拉夸里亚创药株式会社 | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 |
WO2010000469A2 (en) * | 2008-07-03 | 2010-01-07 | Ratiopharm Gmbh | Crystalline salts of sitagliptin |
WO2016117814A2 (ko) * | 2015-01-20 | 2016-07-28 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR101829706B1 (ko) | 2018-02-19 |
US11535610B2 (en) | 2022-12-27 |
CN109769392B (zh) | 2022-06-24 |
US20230192670A1 (en) | 2023-06-22 |
TWI659028B (zh) | 2019-05-11 |
JOP20170172B1 (ar) | 2022-03-14 |
EP3517528A1 (en) | 2019-07-31 |
MX2019003171A (es) | 2019-06-10 |
TW201815786A (zh) | 2018-05-01 |
BR112019005505A2 (pt) | 2019-06-04 |
ES2896802T3 (es) | 2022-02-25 |
US20240150331A1 (en) | 2024-05-09 |
MY197242A (en) | 2023-06-07 |
EP3517528A4 (en) | 2020-05-20 |
WO2018056697A1 (ko) | 2018-03-29 |
JOP20170172A1 (ar) | 2019-01-30 |
JP2019529557A (ja) | 2019-10-17 |
JP6814891B2 (ja) | 2021-01-20 |
US20210292307A1 (en) | 2021-09-23 |
AR109679A1 (es) | 2019-01-09 |
PH12019500602A1 (en) | 2019-11-11 |
US11912690B2 (en) | 2024-02-27 |
EP3517528B1 (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109769392A (zh) | 苯并咪唑衍生物的酸加成盐 | |
JP2021185200A (ja) | (e)−n−{4−[3−クロロ−4−(2−ピリジニルメトキシ)アニリノ]−3−シアノ−7−エトキシ−6−キノリニル}−4−(ジメチルアミノ)−2−ブテンアミドのマレイン酸塩およびその結晶形態 | |
JP3457945B2 (ja) | オメプラゾールの新規な結晶形 | |
JP5043825B2 (ja) | Dpp−iv阻害剤の新規な塩及び多形 | |
US20040229777A1 (en) | Crystalline phases of a potent HCV inhibitor | |
SK76599A3 (en) | S-enantiomer of omeprazole in a neutral form, process for its preparation, pharmaceutical composition containing it and its use | |
US20150166530A1 (en) | Crystalline Salts of a Potent HCV Inhibitor | |
JP2013519665A (ja) | メシル酸イマチニブのα形の製造方法 | |
JP2015508090A (ja) | 固体形態のダビガトランエテキシレートメシレート及びその調製方法 | |
TW201514165A (zh) | D-葡萄糖醇,1-脫氧-1-(甲胺基)-,-1-(6-胺基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氫-7-(3-羥基氮雜環丁烷-1-基)-4-側氧基-3-喹啉羧酸的結晶形態與其製備程序 | |
ES2463681T3 (es) | Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6-oxopirimidin-1 (6H)-il]-N-(2-hidroxietil)-4-metilbenzamida | |
AU2021381516A1 (en) | Integrin inhibitor and uses thereof | |
JP7038675B2 (ja) | 結晶塩形態 | |
JP7314319B2 (ja) | Cdk9阻害剤の結晶多形体及びその製造方法と用途 | |
EP2626355A1 (en) | Process for the preparation of nilotinib hydrochloride | |
RU2515557C1 (ru) | Фармацевтическая соль 8-метил-7-[5-метил-6-(метиламино)-3-пиридинил]-1-циклопропил-4-оксо-1,4-дигидро-3-хинолинкарбоновой кислоты, ее содержащая фармацевтическая композиция, лекарственное средство и способ лечения или профилактики бактериальных инфекций с помощью вышеуказанной соли | |
CA2164296C (en) | Heterocyclic chemistry | |
WO2010111951A1 (zh) | 普拉格雷氢溴酸盐的晶体 | |
TW201718548A (zh) | 哌嗪(piperazine)衍生物 | |
KR100464526B1 (ko) | 나트륨-수소 교환체 타입 1 억제제 결정 | |
TW201008935A (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
WO2024125361A1 (zh) | N-取代苯基磺酰胺类化合物的固体形式 | |
TW201034673A (en) | Novel salt of 1,3,5-triazine-2,4,6-triamine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40007683 Country of ref document: HK |
|
CB02 | Change of applicant information |
Address after: Han Guoshouershi Applicant after: Inoon Ltd. Address before: Han Guoshouershi Applicant before: CJ HEALTHCARE Corp. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20190517 Assignee: SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK Co.,Ltd. Assignor: Inoon Ltd. Contract record no.: 2016990000057 Denomination of invention: Acid addition salts of Benzimidazole derivatives Granted publication date: 20220624 License type: Exclusive License Record date: 20230704 |
|
EE01 | Entry into force of recordation of patent licensing contract |